Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1979 1
1988 1
1989 4
1990 7
1991 1
1992 2
1993 3
1994 1
1995 2
1996 7
1997 5
1998 2
1999 5
2000 12
2001 2
2002 3
2003 2
2004 10
2005 10
2006 11
2007 18
2008 11
2009 10
2010 14
2011 8
2012 7
2013 11
2014 21
2015 16
2016 9
2017 10
2018 8
2019 7
2020 9
2021 14
2022 16
2023 6
2024 13
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

276 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Pharmacology of the Synthetic Cathinone Mephedrone.
Papaseit E, Moltó J, Muga R, Torrens M, de la Torre R, Farré M. Papaseit E, et al. Among authors: molto j. Curr Top Behav Neurosci. 2017;32:313-331. doi: 10.1007/7854_2016_61. Curr Top Behav Neurosci. 2017. PMID: 28012094 Review.
Immune responses associated with mpox viral clearance in men with and without HIV in Spain: a multisite, observational, prospective cohort study.
Moraes-Cardoso I, Benet S, Carabelli J, Perez-Zsolt D, Mendoza A, Rivero A, Alemany A, Descalzo V, Alarcón-Soto Y, Grifoni A, Sette A, Moltó J, Marc A, Marks M, Mitjà O, Brander C, Paredes R, Izquierdo-Useros N, Carrillo J, Suñer C, Olvera A, Mothe B; MoViE-Immune study group. Moraes-Cardoso I, et al. Among authors: molto j. Lancet Microbe. 2024 Aug;5(8):100859. doi: 10.1016/S2666-5247(24)00074-0. Epub 2024 Jun 7. Lancet Microbe. 2024. PMID: 38857615 Free article.
Hodgkin Lymphoma in People Living with HIV.
Navarro JT, Moltó J, Tapia G, Ribera JM. Navarro JT, et al. Among authors: molto j. Cancers (Basel). 2021 Aug 29;13(17):4366. doi: 10.3390/cancers13174366. Cancers (Basel). 2021. PMID: 34503176 Free PMC article. Review.
Diffuse Large B-Cell Lymphoma in the HIV Setting.
Huguet M, Navarro JT, Moltó J, Ribera JM, Tapia G. Huguet M, et al. Among authors: molto j. Cancers (Basel). 2023 Jun 15;15(12):3191. doi: 10.3390/cancers15123191. Cancers (Basel). 2023. PMID: 37370801 Free PMC article. Review.
Biomarkers of Exposure to Zearalenone in In Vivo and In Vitro Studies.
Llorens P, Herrera M, Juan-García A, Payá JJ, Moltó JC, Ariño A, Juan C. Llorens P, et al. Among authors: molto jc. Toxins (Basel). 2022 Apr 20;14(5):291. doi: 10.3390/toxins14050291. Toxins (Basel). 2022. PMID: 35622538 Free PMC article. Review.
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.
Bailón L, Llano A, Cedeño S, Escribà T, Rosás-Umbert M, Parera M, Casadellà M, Lopez M, Pérez F, Oriol-Tordera B, Ruiz-Riol M, Coll J, Perez F, Rivero À, Leselbaum AR, McGowan I, Sengupta D, Wee EG, Hanke T, Paredes R, Alarcón-Soto Y, Clotet B, Noguera-Julian M, Brander C, Molto J, Mothe B; AELIX002 Study Group. Bailón L, et al. Among authors: molto j. Nat Med. 2022 Dec;28(12):2611-2621. doi: 10.1038/s41591-022-02060-2. Epub 2022 Oct 27. Nat Med. 2022. PMID: 36302893 Clinical Trial.
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial.
Bailón L, Moltó J, Curran A, Cadiñanos J, Carlos Lopez Bernaldo de Quirós J, de Los Santos I, Ambrosioni J, Imaz A, Benet S, Suanzes P, Navarro J, González-García J, Busca C, Pérez-Latorre L, Berenguer J, García-Fraile LJ, Mejía-Abril G, Miró JM, Scévola S, Moreno S, Domingo P, Tian Y, Frankot M, Lim D, Cai Y, Vendrame E, Guo S, Wallin JJ, Geleziunas R, SenGupta D, Alarcón-Soto Y, Leal I, Aranguen A, Garcia-Garcia M, McGowan I, Brander C, Arribas JR, Mothe B; AELIX-003 Study Group. Bailón L, et al. Among authors: molto j. Nat Commun. 2025 Mar 4;16(1):2146. doi: 10.1038/s41467-025-57284-w. Nat Commun. 2025. PMID: 40038256 Free PMC article. Clinical Trial.
Early virological failure with cabotegravir/rilpivirine.
Bailón L, Sábato S, Coll J, Santos JR, Miranda C, Puig T, D Avolio A, Paredes R, Moltó J, Negredo E. Bailón L, et al. Among authors: molto j. J Antimicrob Chemother. 2024 May 2;79(5):1193-1194. doi: 10.1093/jac/dkae044. J Antimicrob Chemother. 2024. PMID: 38385520 No abstract available.
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).
Stemler J, Yeghiazaryan L, Stephan C, Mohn KG, Carcas-Sansuan AJ, Rodriguez ER, Moltó J, Mitxeltorena IV, Welte T, Zablockienė B, Akova M, Bethe U, Heringer S, Salmanton-García J, Jeck J, Tischmann L, Zarrouk M, Cüppers A, Biehl LM, Grothe J, Mellinghoff SC, Nacov JA, Neuhann JM, Sprute R, Frías-Iniesta J, Negi R, Gaillard C, Saini G, León AG, Mallon PWG, Lammens C, Hotterbeekx A, Loens K, Malhotra-Kumar S, Goossens H, Kumar-Singh S, König F, Posch M, Koehler P, Cornely OA; EU-COVAT-1 AGED study group on behalf of the VACCELERATE consortium. Stemler J, et al. Among authors: molto j. Int J Infect Dis. 2024 Sep;146:107161. doi: 10.1016/j.ijid.2024.107161. Epub 2024 Jul 9. Int J Infect Dis. 2024. PMID: 38992789 Free article. Clinical Trial.
Aging in HIV-Infected Subjects: A New Scenario and a New View.
Negredo E, Back D, Blanco JR, Blanco J, Erlandson KM, Garolera M, Guaraldi G, Mallon P, Moltó J, Serra JA, Clotet B. Negredo E, et al. Among authors: molto j. Biomed Res Int. 2017;2017:5897298. doi: 10.1155/2017/5897298. Epub 2017 Dec 21. Biomed Res Int. 2017. PMID: 29430462 Free PMC article. Review.
276 results